Trial Watch No. 15
Gene Editing Enters Mass-Market Cardiovascular Disease
Where conviction is building in clinical development, in real time. CRISPR Therapeutics opened CTX340 (NCT07758634), the first-in-human trial of in vivo lipid-nanoparticle CRISPR-Cas9 editing of the angiotensinogen (AGT) gene for essential hypertension. Two Phase 3s open in atopic dermatitis in the same window, and psychedelics reach VA-scale Phase 3.
Summary Layer
The first half of August 2026 pushes gene editing into mass-market cardiovascular disease. CRISPR Therapeutics opened CTX340 (NCT07758634); the first-in-human trial of in vivo lipid-nanoparticle CRISPR-Cas9 editing of the angiotensinogen (AGT) gene for essential hypertension. Until now, in vivo CRISPR editing has been reserved for rare monogenic disease. AGT editing tests whether one-and-done genetic surgery can compete with the world's most-prescribed drug class.
Two Phase 3s open in atopic dermatitis in the same window. Nektar's Rezpegaldesleukin (regulatory T-cell IL-2 agonist, 510 pts) and Pfizer's Tilrekimig (anti-IL-13/IL-33 combination, 375 pts) both entered Phase 3 monotherapy or combination testing in moderate-to-severe AD; two distinct mechanisms positioning to compete for the post-dupilumab market.
Psychedelics reach VA-scale Phase 3. The VA Office of R&D's multi-site Phase 3 of psilocybin for treatment-resistant depression in veterans (240 pts, 5 sites) is the first federal-scale psychedelic Phase 3. Combined with Otsuka's Phase 3 of ulotaront (SEP-363856, a TAAR1 agonist inherited via Sunovion/Sumitomo) for generalized anxiety disorder, the mental health field is now in definitive Phase 3 execution mode. 15 high-signal trials across oncology, cardiometabolic, immunology, neurology, and advanced modalities.
Therapeutic Areas Covered
Oncology
5 trialsZanzalintinib ± SC Pembrolizumab in Stage II/III CRC With Molecular Residual Disease
Phase 3 · Oncology; CRC MRD-directed
Timeline
Start August 6, 2026; Primary completion April 2030
Mechanism
Zanzalintinib (Exelixis's next-generation multi-kinase inhibitor; cabozantinib's successor targeting VEGFRs, MET, and AXL) combined with subcutaneous pembrolizumab + berahyaluronidase alfa (MK-3475A). Enrollment restricted to ctDNA-positive Stage II/III colorectal cancer after definitive therapy.
Why It Matters
First Phase 3 in Stage II/III CRC to use ctDNA-defined molecular residual disease (MRD) as the trial entry criterion. Every prior adjuvant CRC trial dosed patients based on stage; this one only enrolls those with detectable ctDNA post-surgery. If positive, it establishes MRD-adaptive adjuvant therapy as a new paradigm; and validates subcutaneous pembrolizumab combinations across the Merck IO franchise.
PANKU-Breast04 · BL-B01D1 + PD-1 vs. Nab-Paclitaxel + PD-1 in First-Line PD-L1+ TNBC
Phase 3 · Oncology; first-line PD-L1+ TNBC
Timeline
Start August 2026; Primary completion December 2029
Mechanism
BL-B01D1 is Sichuan Baili's EGFR/HER3 bispecific antibody-drug conjugate (topoisomerase I inhibitor payload). Tested vs. nab-paclitaxel; each backbone paired with the same anti-PD-1; in previously untreated, PD-L1-expressing metastatic triple-negative breast cancer.
Why It Matters
BL-B01D1 is the same EGFR/HER3 bispecific ADC that SystImmune licensed to Bristol Myers Squibb in April 2024 for $800M upfront + up to $8.4B in milestones; the largest China-to-US licensing deal on record for an ADC. PANKU-Breast04 is one of the pivotal readouts that determines whether the BMS deal delivers a franchise. Bispecific ADC entering front-line TNBC as monotherapy replacement for taxane chemotherapy signals a bigger reset than any single incremental ADC approval.
Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed and R/R Burkitt and High-Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
Phase 2/3 · Oncology; Burkitt / high-grade double-hit lymphoma
Timeline
Start August 14, 2026; Primary completion November 2033
Mechanism
Glofitamab (Roche's CD20xCD3 bispecific, approved 2023 for r/r DLBCL) layered onto intensive chemoimmunotherapy backbones (R-EPOCH / R-CODOX-M-IVAC-style) in Burkitt lymphoma and high-grade double-hit / triple-hit B-cell lymphomas with MYC + BCL2 rearrangements.
Why It Matters
Double-hit high-grade B-cell lymphomas have among the worst outcomes in aggressive lymphoma; standard immunochemotherapy alone fails many patients within 12 months. This is the first Phase 2/3 evaluating a CD20xCD3 bispecific inside intensive front-line regimens for the aggressive-histology population. If positive, it opens front-line intensification with bispecifics for the hardest-to-treat aggressive lymphomas.
BLB101 vs. Blincyto® (Blinatumomab) Biosimilar Comparability in R/R CD19+ B-ALL
Phase 3 · Oncology; biosimilar blinatumomab
Timeline
Start August 9, 2026; Primary completion October 2027
Mechanism
Comparability study of BLB101 (proposed blinatumomab biosimilar) versus reference Blincyto® in adults with r/r CD19+ B-cell acute lymphoblastic leukemia. Assesses pharmacokinetics, efficacy, safety, and immunogenicity.
Why It Matters
First registered Phase 3 comparability program for a blinatumomab biosimilar. Blinatumomab (Amgen) is the reference BiTE; used across R/R B-ALL, MRD-positive B-ALL, and now front-line consolidation (E1910 study data). Biosimilar entry into the bispecific/BiTE category signals maturation of the entire cell-engager class beyond monoclonal antibody biosimilars.
ELDORADO · Elranatamab vs. Daratumumab (Each With RVd Lite) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Phase 2 · Oncology; newly diagnosed multiple myeloma
Timeline
Start August 1, 2026; Primary completion December 2030
Mechanism
Head-to-head Phase 2 of Elranatamab (Pfizer's BCMAxCD3 bispecific, approved 2023) vs. Daratumumab (Janssen's anti-CD38 backbone); each combined with lenalidomide + bortezomib + dexamethasone lite regimen; in transplant-ineligible/deferred newly diagnosed multiple myeloma.
Why It Matters
First head-to-head between a BCMA bispecific and a CD38 antibody in the front-line ineligible setting. Daratumumab-based quadruplet is the current standard; if elranatamab wins on efficacy or MRD rates, the front-line NDMM standard shifts to a BCMA bispecific; a major franchise disruption for Janssen/Genmab (Darzalex) and franchise expansion for Pfizer/OncBioMune (Elrexfio).
Verified sources
Cardiometabolic
5 trialsCTX340 · First-in-Human LNP-CRISPR In Vivo Editing of the Angiotensinogen Gene in Hypertension
Phase 1/2 · Cardiometabolic; hypertension (in vivo CRISPR)
Timeline
Start August 8, 2026; Primary completion July 2028
Mechanism
CTX340 is a lipid-nanoparticle-delivered CRISPR-guide-RNA/Cas9 formulation that permanently disrupts the hepatic angiotensinogen (AGT) gene in vivo. AGT is the upstream substrate of the renin-angiotensin system; a single infusion knocks it down for the patient's lifetime, mimicking the phenotype of AGT deficiency.
Why It Matters
Until now, in vivo CRISPR editing has been reserved for rare monogenic disease (ATTR, DMD, sickle cell). CTX340 is the first-in-human trial of in vivo CRISPR editing for a common cardiovascular indication. If safe and durable, it validates one-time gene editing as a competitor to daily antihypertensives; a $30B market. Verve Therapeutics has parallel base-editing approaches (PCSK9, ANGPTL3, LPA) but CRISPR Therapeutics is the first to reach AGT clinically. A watershed program for the entire "gene editing as chronic-disease therapy" thesis.
UNIGUIDE-1 · UBT251 Injection in T2D With Inadequate Glycemic Control on Diet Alone
Phase 3 · Cardiometabolic; T2D first-line
Timeline
Start August 10, 2026; Primary completion September 2027
Mechanism
UBT251 is a GLP-1/glucagon/GIP triple agonist tested at 2, 4, and 6 mg doses vs. matching placebo in Type 2 diabetes with inadequate control on diet + exercise alone. UNIGUIDE-1 is the placebo-controlled first-line pillar; UNIGUIDE-2 (Edition 14) was the semaglutide head-to-head second-line.
Why It Matters
Retatrutide (Lilly) is the only other triple agonist in late-stage development. UBT251 now runs three parallel Phase 3s in obesity (Edition 12), T2D on metformin (Edition 14), and treatment-naive T2D (this trial); the fastest Phase 3 buildout of any Chinese-originated cardiometabolic asset. If UBT251 hits, it becomes the first Chinese biotech-originated triple agonist to reach global regulatory filings.
Verified sources
ABBV-295 · Dose-Finding Phase 2 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Phase 2 · Cardiometabolic; obesity (AbbVie entry)
Timeline
Start August 7, 2026; Primary completion March 2028
Mechanism
ABBV-295 is AbbVie's investigational obesity asset; first solo-branded Phase 2 declaration for the company in metabolic disease. Dose-finding across weight-related comorbidities.
Why It Matters
AbbVie becomes the tenth major sponsor to enter clinical obesity development, joining Novo, Lilly, Amgen, Pfizer, Roche, BI, Structure, AZ, Regeneron, and UBT. AbbVie has been conspicuously absent from the obesity race despite its immunology franchise; ABBV-295 is the entry ticket. Dose-finding at 360 patients signals AbbVie is committing at Phase 2 scale to determine whether the asset can differentiate on tolerability, weight-related comorbidity, or long-term maintenance.
Verified sources
MAVRIC · Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
Phase 3 · Cardiometabolic; IPF repurposing
Timeline
Start August 1, 2026; Primary completion March 2029
Mechanism
Metformin (approved for T2D since 1957, glucose-lowering via hepatic AMPK activation) repurposed at Phase 3 scale in idiopathic pulmonary fibrosis to test whether it slows progressive respiratory decline. Preclinical work suggests AMPK activation reverses fibroblast metabolic reprogramming.
Why It Matters
Nintedanib and pirfenidone are approved IPF antifibrotics at ~$100K/year each. If a $10/month generic slows decline meaningfully, it disrupts the entire IPF economic model. 800-patient Phase 3 is unusually large for a repurposing trial; signals genuine confidence in the AMPK / fibroblast metabolism thesis. Third repurposed-generic Phase 3 trial in the KITSA tracking window (after Edition 14's UCL AD SMART trial atomoxetine + metformin arms).
Verified sources
HFrEF Polypill in Sri Lanka; Multi-Center Type I Hybrid RCT
Phase 3 · Cardiometabolic; heart failure polypill
Timeline
Start August 2026; Primary completion April 2029
Mechanism
Fixed-dose combination polypill of guideline-directed heart failure medical therapy vs. usual sequential titration care in patients with heart failure with reduced ejection fraction (HFrEF). Type I hybrid effectiveness-implementation design tests both efficacy and real-world adoption.
Why It Matters
Guideline-directed HFrEF therapy (ARNi + beta-blocker + MRA + SGLT2i, the "four pillars") is proven; but real-world uptake remains dismal because sequential titration is slow and complex. A single polypill collapses four pills into one, targeting the compliance and titration barrier that limits mortality benefit in LMICs and underserved US populations. If effective, it re-architects heart failure delivery globally.
Verified sources
Immunology
3 trialsRezpegaldesleukin (NKTR-358) Monotherapy in Moderate-to-Severe Atopic Dermatitis (Age ≥12)
Phase 3 · Immunology; atopic dermatitis (Treg IL-2)
Timeline
Start August 2026; Primary completion June 2028
Mechanism
Rezpegaldesleukin (NKTR-358) is Nektar's regulatory T-cell (Treg)-selective IL-2 pathway agonist; engineered to expand endogenous Tregs without expanding effector T cells. First Phase 3 monotherapy in moderate-to-severe atopic dermatitis after prior collaboration with Eli Lilly (which returned rights in 2023).
Why It Matters
Post-Lilly-return, this is Nektar's first solo Phase 3 in AD; the go/no-go moment for rezpegaldesleukin. Treg expansion is a fundamentally different mechanism than IL-4/13 (dupilumab), IL-13 (tralokinumab, lebrikizumab), or JAK inhibitors; targeting the source of dysregulated immunity rather than downstream cytokines. If it hits, it opens the door to Treg expansion for lupus, IBD, T1D, and beyond.
Verified sources
Tilrekimig Combination Therapy in Adult and Adolescent Moderate-to-Severe Atopic Dermatitis
Phase 3 · Immunology; atopic dermatitis (Pfizer combination)
Timeline
Start August 14, 2026; Primary completion February 2028
Mechanism
Tilrekimig is Pfizer's Type 2 inflammation antibody in a combination therapy Phase 3 for moderate-to-severe atopic dermatitis in patients ≥12 years old. Pfizer's second-generation approach to AD after abrocitinib (Cibinqo).
Why It Matters
Second AD Phase 3 opening in the same 2-week window, alongside Nektar's Rezpegaldesleukin. Pfizer positioning tilrekimig as combination therapy signals commitment to head-to-head competition with dupilumab (Sanofi/Regeneron's $10B+ franchise); instead of monotherapy differentiation, Pfizer bets on combo mechanisms. Together with Rezpegaldesleukin, the AD field enters a new competitive phase where post-dupilumab share depends on differentiated MOA plus combination logic.
Verified sources
Momelotinib in Participants With VEXAS Syndrome; First Phase 2/3 in the Indication
Phase 2/3 · Immunology; VEXAS syndrome (first pivotal)
Timeline
Start August 5, 2026; Primary completion December 2028
Mechanism
Momelotinib (GSK's JAK1/JAK2/ACVR1 inhibitor, approved 2023 for myelofibrosis with anemia) added to glucocorticoid backbone in VEXAS syndrome; the UBA1-mutated adult-onset inflammatory somatic disease first described in 2020.
Why It Matters
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) was discovered in December 2020 via NIH clinical genomics. Estimated prevalence: 13,000-15,000 US patients. There is no approved therapy; patients cycle through steroids, azacitidine, tocilizumab, and JAK inhibitors off-label. This is the first registered Phase 2/3 in VEXAS; six years from disease discovery to pivotal trial. Positive readout would establish the first approved therapy for a disease that didn't exist as a diagnosis before 2020.
Verified sources
Neurology
1 trialSEP-363856 (Ulotaront) Fixed-Dose Phase 3 in Generalized Anxiety Disorder
Phase 3 · Neurology; generalized anxiety disorder
Timeline
Start August 7, 2026; Primary completion October 2028
Mechanism
Ulotaront (SEP-363856) is a TAAR1 agonist / 5-HT1A partial agonist; Sunovion's asset acquired via Sumitomo, now Otsuka. Fixed-dose Phase 3 in generalized anxiety disorder. TAAR1 acts upstream of dopamine and serotonin systems without direct D2 receptor blockade.
Why It Matters
Ulotaront's schizophrenia Phase 3 program (DIAMOND-1, DIAMOND-2) missed in 2023, leading to a strategic re-scoping. Expansion into GAD tests the TAAR1 hypothesis in a broader anxiety population. If positive, it would be the first non-benzodiazepine, non-SSRI, non-SNRI approved for GAD in over a decade; validating TAAR1 as a distinct psychiatric mechanism.
Advanced Modalities
1 trialMulti-Site Phase 3 of Psilocybin for Treatment-Resistant Depression in Veterans
Phase 3 · Adv. Modalities; psilocybin (Veterans TRD)
Timeline
Start July 30, 2026; Primary completion December 2030
Mechanism
Psilocybin (5-HT2A receptor agonist) administered under supervised psychotherapy protocol to US military veterans with treatment-resistant major depression. Two-arm dose comparison.
Why It Matters
First federal-scale (VA Office of R&D) multi-site Phase 3 of a psychedelic. The FDA's rejection of Lykos MDMA-PTSD in August 2024 raised the regulatory bar substantially for the entire psychedelic category. A positive Phase 3 in veterans, run inside the VA system with 240 patients across 5 sites, would carry decisive regulatory weight; because the VA is uniquely positioned to establish reproducibility and address the "expectancy bias" concerns that sank Lykos. This is the psychedelic field's second attempt at Phase 3, but its first inside a federal healthcare system.
Verified sources
Signal Convergence
Five patterns across the August 1 to 15 window
1. In vivo CRISPR crosses into mass-market cardiovascular
CRISPR Therapeutics' CTX340 tests in vivo LNP-CRISPR editing of the angiotensinogen (AGT) gene for essential hypertension; the first application of the technology to a common non-monogenic disease. Verve's base-editing programs (PCSK9, ANGPTL3, LPA) target adjacent CV pathways; the field is now racing to establish gene editing as a competitor to daily antihypertensives. A watershed program for the "gene editing as chronic-disease therapy" thesis.
2. Atopic dermatitis becomes a dual-pillar Phase 3 event
Nektar's Rezpegaldesleukin (Treg IL-2 monotherapy, 510 pts) and Pfizer's Tilrekimig (combination therapy, 375 pts) both open Phase 3 in mod-severe AD in the same 2-week window. Two entirely different mechanisms; regulatory T-cell expansion vs. Type 2 cytokine blockade; positioning to fight for post-dupilumab share of a $10B+ franchise.
3. The obesity race adds sponsor #10
AbbVie's ABBV-295 (Phase 2, 360 pts) enters the field alongside UBT251 UNIGUIDE-1 (T2D first-line Phase 3) and Regeneron/Lilly/Amgen ongoing programs. Obesity is now a ten-sponsor clinical race with parallel programs across obesity, T2D, COPD, and CV risk; the fastest cross-indication expansion in modern pharma history.
4. Psychedelics reach VA-scale Phase 3, and psychiatry writ large enters Phase 3 execution
VA's psilocybin TRD Phase 3 (240 pts, 5 sites) is the first federal-scale psychedelic pivotal. Otsuka's ulotaront TAAR1 GAD Phase 3 (384 pts) tests a mechanism that failed in schizophrenia. The mental health field is now converting Phase 2 momentum into regulatory readout timelines.
5. Rare and undrugged indications get their first pivotals; six years faster than the historical benchmark
GSK's momelotinib in VEXAS syndrome is the first Phase 2/3 in a disease entity described in December 2020; six years from discovery to pivotal. Combined with Edition 14's post-CAR-T supportive care Phase 3 and repurposed generics reaching Phase 3 (metformin in IPF), biopharma is closing the gap between disease description and definitive intervention faster than at any prior point.
Underlying truth: the boundary between "unmet need" and "definitive Phase 3" is collapsing. Gene editing for hypertension. Six-year path from disease discovery to pivotal in VEXAS. Federal-scale psychedelic trials. Repurposed generics in Phase 3 for orphan pulmonary indications. The categories that used to sit outside biopharma's execution zone are now inside it.
Continue Tracking
Trial Watch is Kitsa's clinical intelligence layer. Edition 16 (August 16 to 31, 2026) drops on August 31.
On Verification
Every trial in this edition is anchored to ClinicalTrials.gov and cleaned secondary validation sources where available. Dead registry shell links, generic sponsor homepages, and "search this portal" links have been removed. Remaining links point to exact trial pages, direct registry copies, institutional trial pages, sponsor program sources, or publication/source pages that visibly support the listed trial, drug, NCT ID, acronym, sponsor, or program. One date-gate item requires final editorial confirmation: NCT07226232 has a direct source showing a July 30, 2026 start date, so confirm whether it should remain in the August 1 to August 15 edition or be replaced.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.